But if fusion is in your future, you’ve been giving yourself a fair number of years to be able to go back to that, if that is a solution. The challenge with going to fusion right away and in fact that, as you know, you start having to have the next level fusions done. And so from our side, when we look at it and where this is positioned and how we can go after it, I think it’s a great opportunity. Additionally, the reimbursement in the ambulatory surgery center world has actually gone up really nicely. So when you compare it to the other procedures such as laminectomy, this is a very, very profitable procedure, if you will. And clinically, arguably, this is a great, great, great solution for any surgeon who has a patient, and quite frankly wants to stave off any type of infusion for quite some time.
And so that’s kind of how we’re positioned. That’s how we’re looking at it. And then when you look at what we’re rolling out with respect to our pipeline of new products, certainly on the biologic side, so two things. One of the things that we’ve had a challenge with on our side is the supply of our OsteoVive Plus. We cannot make enough of it. We can’t get enough of it out the door. So that’s still a product line that has a fair amount of room left to grow. And so we’re still focused on OsteoVive Plus as well as OsteoFactor, which OsteoFactor factor again is our growth factor product, which again, we can’t sell enough of it. And it’s going very, very well. And if there are additions, and again, you got to be careful when you’re rolling out products, you don’t want to take any steam out of something that’s working really well.
We will have some additions, for instance, the OsteoVive Plus side. We also will have — there’s several other products that are queued up. It’s a matter of when we decide to actually release them because again, we want to make sure we’re getting as much out of these and giving all of our distributors and surgeons the opportunity to grow with these products as far as they can. So that’s within the pipeline right now, and that’s where our focus is. But if — yeah, there’s certainly more to come over the course of the next few years, but that’s where we are today.
Kyle Rose: Thank you.
Operator: There are no additional questions at this time. I’d like to turn the call back to Sean Browne for closing remarks.
Sean Browne: Great. Thank you. We are off to a great start in 2023, highlighted by a robust organic growth, led by continued demand for our leading biologics products and initial contributions from our recently acquired Coflex and Cofix product lines. With our strategic growth pillars beginning to materialize in the form of strong revenues and efficient operations, we are poised to continue building on this upward trajectory as we scale the business. Moreover, the initiation of annual revenue guidance for 2023 further illustrates our confidence in our business and strategy. And then finally, the success of our mission of honoring the gift of donation by allowing our patients to live as full and complete a life as possible is only made possible by our valuable employees. I would like to thank them for their continued dedication to bringing our life-changing solutions to patients in need. Thank you for joining us today and for your continued support.
Operator: This concludes today’s conference. You may disconnect your lines at this time and thank you for your participation.
